Last updated: November 6, 2026
Acetaminophen and codeine phosphate is a mature, low-margin opioid combination dominated by generic manufacturers. Its financial trajectory is shaped by declining opioid utilization, state and federal prescribing controls, low unit prices, manufacturing concentration, and intermittent supply disruptions rather than by patent protection. In the United States, branded revenue is limited, Orange Book exclusivity is not a meaningful barrier, and generic competition is established across tablets and oral solutions.
The product retains demand for short-term treatment of moderate pain when non-opioid therapy is inadequate. Its commercial ceiling is constrained by codeine’s variable metabolism, acetaminophen hepatotoxicity risk, pediatric restrictions, and the availability of non-opioid and alternative opioid therapies.
What is the market position of acetaminophen and codeine phosphate?
Acetaminophen and codeine phosphate combines a non-opioid analgesic with a low-potency opioid. U.S. products commonly contain 300 mg of acetaminophen with 15 mg, 30 mg, or 60 mg of codeine phosphate per tablet. Oral solutions are also marketed in pediatric and adult concentrations.
| Product characteristic |
Market implication |
| Active ingredients |
Acetaminophen and codeine phosphate |
| Primary use |
Short-term relief of moderate pain |
| Common tablet strengths |
300/15 mg, 300/30 mg, and 300/60 mg |
| U.S. controlled-substance status |
Generally Schedule III for combination products containing limited quantities of codeine |
| Primary market structure |
Generic and multi-source |
| Branded reference product |
Tylenol with Codeine and related historical brands |
| Patent dependence |
Minimal for the core immediate-release product |
| Main commercial risks |
Opioid controls, acetaminophen safety limits, demand erosion, and supply interruptions |
The product is no longer a growth medicine. Demand is concentrated in emergency medicine, dental prescribing, postoperative care, primary care, and selected chronic pain situations. Prescribers increasingly favor ibuprofen, naproxen, acetaminophen alone, tramadol, hydrocodone combinations, or oxycodone products depending on the indication and regulatory setting.
How large is the acetaminophen-codeine market?
No reliable public financial series isolates U.S. sales of acetaminophen and codeine phosphate across all manufacturers, strengths, dosage forms, institutional contracts, retail prescriptions, and international markets. Generic manufacturers usually report revenue at portfolio or segment level rather than by this product.
The product’s market value is best understood through its structure:
- Generic tablets account for most U.S. volume.
- Retail prices are compressed by multiple suppliers and pharmacy benefit substitution.
- Oral solutions have higher manufacturing and distribution complexity but limited volume.
- Hospital and government contracts exert price pressure.
- Revenue has shifted from branded products to low-price generic supply.
Historical branded sales for Tylenol with Codeine have not generally been reported as a separate line item by Johnson & Johnson or other brand owners. Generic product revenue is also not separately disclosed by major suppliers such as Teva, Amneal, Hikma, or other companies when included within broader generic portfolios.
The financial profile is therefore characterized by high prescription familiarity but low supplier-level revenue visibility. Volume can remain material while per-unit revenue declines.
What is the financial trajectory of acetaminophen and codeine phosphate?
The long-term financial trajectory is declining or flat in nominal terms for most suppliers, with temporary price increases during shortages. The main drivers are:
| Driver |
Direction |
Financial effect |
| Opioid prescribing restrictions |
Negative |
Reduces prescription volume |
| Generic competition |
Negative |
Compresses selling prices |
| Pediatric restrictions |
Negative |
Reduces pediatric use and oral-solution demand |
| Shortage conditions |
Mixed |
Can increase prices but reduce reliable supply |
| Hospital purchasing |
Negative |
Increases contract-price pressure |
| Established manufacturing processes |
Positive |
Limits development cost |
| Alternative analgesics |
Negative |
Substitutes for combination therapy |
| Brand erosion |
Negative |
Reduces premium pricing |
Generic manufacturers can still earn acceptable contribution margins when they have efficient production, established pharmacy contracts, or temporary supply advantages. The product does not usually justify large clinical development programs because the active ingredients are old, the regulatory pathway is established, and new formulations face limited commercial upside.
Financial exposure is more significant for manufacturers with broad generic portfolios than for any single company. A supplier can lose share quickly if it experiences a quality action, active pharmaceutical ingredient shortage, packaging interruption, or controlled-substance quota constraint.
When does acetaminophen and codeine phosphate lose exclusivity?
The core immediate-release product lost practical exclusivity decades ago. Acetaminophen and codeine phosphate is an off-patent combination available from multiple generic manufacturers.
The commercial exclusivity profile is:
| Exclusivity category |
Status |
| Core active ingredients |
Long expired |
| Immediate-release tablet composition |
Generally off-patent |
| Basic oral-solution formulation |
Generally off-patent |
| New chemical entity exclusivity |
Not applicable |
| Orphan-drug exclusivity |
Not applicable |
| Biosimilar exclusivity |
Not applicable |
| Pediatric exclusivity |
No current market barrier for the core product |
| Generic competition |
Established |
The product is a small-molecule combination, not a biologic. Biosimilar competition is therefore irrelevant. Competitive entry occurs through abbreviated new drug applications, state procurement, wholesaler agreements, and manufacturing capacity rather than through biosimilar interchangeability.
What patents protect acetaminophen and codeine phosphate?
No active patent estate is generally recognized as a meaningful barrier to generic production of the conventional immediate-release acetaminophen-codeine tablet. Historical patents covering the combination, ordinary dosage forms, or basic manufacturing processes have expired or have limited practical value.
Potentially relevant intellectual-property categories include:
- Modified-release formulations.
- Abuse-deterrent delivery systems.
- Taste-masked oral solutions.
- Transdermal or buccal delivery systems.
- Combination products with additional active ingredients.
- Manufacturing processes that improve stability or yield.
These rights would protect a particular formulation or delivery system, not the conventional immediate-release combination as a whole. A manufacturer seeking to enter the standard tablet market would generally rely on an ANDA and would not need to license a foundational patent for acetaminophen-codeine.
Are there formulation patents for acetaminophen and codeine phosphate?
Formulation patents can matter where a product has a distinct release profile, excipient system, abuse-deterrent feature, or liquid-stability profile. Their commercial value is limited unless the formulation has regulatory approval, physician adoption, and a defensible reimbursement position.
Standard 300/30 mg and 300/60 mg immediate-release tablets do not normally carry the type of formulation protection associated with newer branded products. Any patent analysis must be performed at the product level because different strengths, dosage forms, and manufacturers may have separate regulatory records.
What is the Orange Book status of acetaminophen and codeine phosphate?
The FDA Orange Book identifies approved drug products and patents or exclusivity relevant to listed reference products. For acetaminophen-codeine products, the practical Orange Book question is whether a specific listed product has an unexpired patent or exclusivity code that blocks an ANDA applicant.
For the mature immediate-release product, the commercial answer is generally no meaningful barrier. Many products are approved as generic equivalents or through legacy approvals, while the historical branded product does not create a durable monopoly over the active ingredients.
An Orange Book listing does not itself prove that every manufacturer faces the same patent position. The relevant analysis depends on:
- The exact NDA or ANDA.
- Strength and dosage form.
- Listed patent numbers.
- Patent expiration dates.
- Pediatric or other exclusivity codes.
- Paragraph IV certifications filed by an applicant.
Which companies are challenging acetaminophen-codeine patents?
There is no major current Paragraph IV campaign comparable to the challenges associated with high-value branded medicines. The conventional product has long been exposed to generic competition, so the principal commercial contest is among existing generic suppliers.
Potential suppliers in the U.S. generic market have included large manufacturers such as Teva, Amneal, Hikma, Endo or Par-related operations, and other ANDA holders. Product availability changes because companies discontinue products, transfer approvals, exit low-margin categories, or suspend production.
The absence of a major Paragraph IV dispute is itself commercially important. It indicates that the product’s value lies in manufacturing and distribution economics, not in litigation-based entry timing.
What FDA regulatory restrictions affect codeine combinations?
FDA restrictions have materially reduced the addressable market.
In 2017, FDA required labeling changes warning against codeine use in children younger than 12 and recommending against use in adolescents aged 12 to 18 who are obese or have conditions such as obstructive sleep apnea or severe lung disease. FDA also warned against breastfeeding when the mother is an ultrarapid metabolizer of codeine because of the risk of excessive morphine exposure in the infant (FDA, 2017).
The product also carries acetaminophen-related risk. Total daily acetaminophen exposure from all prescription, over-the-counter, and combination medicines must be controlled to reduce the risk of acute liver failure. FDA previously required prescription combination products containing more than 325 mg of acetaminophen per dosage unit to be limited to 325 mg or less, affecting several opioid combinations and prescribing practices (FDA, 2011).
Codeine’s pharmacogenomic variability further weakens its clinical position. CYP2D6 ultrarapid metabolizers can convert codeine to morphine more rapidly, increasing toxicity risk, while poor metabolizers may obtain limited analgesic benefit.
What litigation and settlement agreements affect the product?
No prominent, product-specific patent litigation or settlement agreement currently defines the U.S. market for conventional acetaminophen-codeine tablets. The more important legal exposure comes from opioid marketing, controlled-substance distribution, product liability, and state enforcement.
Relevant legal risks include:
- Failure to comply with controlled-substance recordkeeping.
- Diversion through wholesalers or pharmacies.
- Inadequate warnings regarding respiratory depression.
- Pediatric or breastfeeding use outside labeled restrictions.
- Acetaminophen overdose and liver injury claims.
- State opioid-abatement agreements.
- Manufacturing deviations and FDA enforcement actions.
The product may be included within broader opioid litigation inventories, but that does not create a product-specific exclusivity event or a conventional patent settlement. Manufacturers with large opioid portfolios can face material legal costs even when the individual product contributes modest revenue.
What generic entry risks exist for acetaminophen and codeine phosphate?
Generic entry risk is high because the market is mature and technically accessible. The main barriers are commercial rather than patent-based.
Manufacturing and supply barriers
Manufacturers must manage:
- Controlled-substance handling and security.
- DEA quota and reporting requirements.
- Acetaminophen and codeine API sourcing.
- Content uniformity and dissolution testing.
- Stability of oral solutions.
- Child-resistant packaging.
- Serialization and traceability.
- Pharmacovigilance and abuse-diversion controls.
These requirements can reduce the number of reliable suppliers even when legal entry is open. A shortage can occur when several manufacturers exit simultaneously or when a single API or packaging supplier fails.
Generic launch scenarios
| Scenario |
Likely market result |
| New tablet ANDA entrant |
Lower prices and rapid share fragmentation |
| Existing supplier exits |
Temporary price increases and pharmacy backorders |
| Oral-solution entrant |
Higher technical burden but limited market size |
| Manufacturing recall |
Short-term substitution toward remaining suppliers |
| New abuse-deterrent formulation |
Limited uptake unless reimbursement supports premium pricing |
| Tighter opioid controls |
Structural volume decline |
How does acetaminophen-codeine compare with competing analgesics?
| Product |
Relative market position |
Key commercial advantage |
Key weakness |
| Acetaminophen alone |
Broad, low-cost |
No opioid controls |
Lower efficacy for some moderate pain |
| Ibuprofen or naproxen |
Strong non-opioid alternative |
Anti-inflammatory activity |
Gastrointestinal, renal, and cardiovascular risks |
| Acetaminophen-codeine |
Mature opioid combination |
Familiar and inexpensive |
Variable metabolism and opioid restrictions |
| Tramadol |
Alternative weak opioid |
Broad prescribing familiarity |
Controlled-substance and dependence concerns |
| Hydrocodone-acetaminophen |
Stronger opioid option |
Greater analgesic potency |
Greater misuse and respiratory-depression risk |
| Oxycodone products |
Higher-potency option |
Effective for severe pain |
Higher regulatory and abuse risk |
Acetaminophen-codeine is most vulnerable where clinicians can achieve acceptable pain control with non-opioid therapy. It retains a role where cost, familiarity, and moderate analgesic potency outweigh concerns about codeine variability.
What is the geographic coverage of the market?
The combination is marketed internationally, but regulatory treatment differs substantially. In the United States, codeine combinations are controlled substances. Canada, Europe, Australia, and other markets apply different prescription, pediatric, scheduling, and pharmacy-dispensing rules.
International revenue is fragmented because:
- Brand names differ by country.
- Strengths and formulations vary.
- Some countries restrict or discourage codeine use.
- Prescription controls differ.
- National health systems negotiate prices.
- Local manufacturing and tender systems affect supply.
The United States remains commercially important because of its large pharmaceutical distribution system, but the product’s worldwide economics remain generic and price-sensitive.
How strong is the patent estate for acetaminophen and codeine phosphate?
The patent estate is weak for the conventional product and potentially stronger only for differentiated delivery systems.
| Patent factor |
Assessment |
| Core molecule protection |
Expired |
| Combination-product protection |
Expired or commercially immaterial |
| Standard tablet protection |
Weak |
| Oral-solution protection |
Limited and product-specific |
| Abuse-deterrent formulation |
Potentially stronger |
| Manufacturing know-how |
Moderate operational value |
| Regulatory exclusivity |
No meaningful current barrier |
| Litigation leverage |
Low |
Manufacturing know-how can produce a practical advantage even where patents do not. Reliable supply, validated processes, API contracts, controlled-substance infrastructure, and wholesaler access may be more valuable than residual intellectual property.
Key Takeaways
- Acetaminophen and codeine phosphate is a mature generic market with no meaningful core-product patent barrier.
- Revenue is not publicly reported in a reliable standalone series.
- The financial trajectory is flat to declining, with temporary price volatility during shortages.
- Generic manufacturers compete mainly on supply reliability, cost, contracts, and regulatory execution.
- FDA pediatric restrictions and acetaminophen safety requirements have reduced the addressable market.
- Biosimilar risk is irrelevant because the product is a small-molecule combination.
- Paragraph IV litigation and patent settlements do not materially shape current competition.
- Formulation patents can matter for abuse-deterrent, modified-release, or specialized liquid products, but not usually for standard immediate-release tablets.
- The largest commercial risks are opioid-policy tightening, manufacturing interruptions, liability exposure, and substitution by non-opioid analgesics.
FAQs
Is acetaminophen with codeine still profitable for generic manufacturers?
It can be profitable at efficient manufacturing sites or during supply shortages, but ordinary market pricing is low. Profitability depends more on volume, capacity utilization, and supply reliability than on premium pricing.
Does Tylenol with Codeine still have market exclusivity?
No broad market exclusivity protects the conventional acetaminophen-codeine combination. Historical brand recognition does not prevent approved generic substitution.
Can a company launch a generic acetaminophen-codeine tablet without a patent license?
Generally, yes, provided the applicant satisfies FDA approval requirements and resolves any patents or exclusivity listed for the specific reference product. The standard immediate-release product is broadly genericized.
Are acetaminophen-codeine products subject to opioid quotas?
Codeine is a controlled substance in the United States, so manufacturers and distributors operate within applicable DEA controls, reporting requirements, and quota systems. These controls can affect supply even when demand remains stable.
What could increase the value of an acetaminophen-codeine product?
A differentiated formulation, reliable shortage-era supply, an abuse-deterrent feature, improved liquid stability, or an established institutional contract could increase commercial value. A new formulation would still face limited growth because opioid utilization and reimbursement remain constrained.
References
-
U.S. Food and Drug Administration. (2011). FDA recommends limiting acetaminophen in prescription combination products to 325 mg per dosage unit. https://www.fda.gov
-
U.S. Food and Drug Administration. (2017). FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. https://www.fda.gov
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov
-
Centers for Disease Control and Prevention. (2022). CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recommendations and Reports, 71(3), 1-95. https://doi.org/10.15585/mmwr.rr7103a1
-
Drug Enforcement Administration. (2023). Controlled substances schedules. U.S. Department of Justice. https://www.deadiversion.usdoj.gov/schedules/
